Floatz logo

Amg 820

Colorectal Cancer

AmMax Bio, Inc.monoclonal_antibodyPhase 1/2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
59/ 100

Competitive context

840 Active assets in the Colorectal Cancer cohort.

View all 50

Same molecule, other indications

Amg 820 is also rated in:

cancerDormant
CC
Indicative ·
46 / 100
View asset →
neoplasmDormant
CC
Indicative ·
46 / 100
View asset →
pancreatic neoplasmDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →